Abstract
Intellia Therapeutics has acquired Rewrite Therapeutics, a developer of DNA-writing technologies, for $45 million plus $155 million in potential milestone payments. Intellia is developing gene-editing therapies based on the CRISPR-Cas9 editing system. The company says Rewrite’s DNA-writing tools, including CRISPR-Cas9-guided polymerases, could provide new ways to edit disease-causing genes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
